AC Immune Beheer

Beheer criteriumcontroles 2/4

De CEO AC Immune is Andrea Pfeifer, benoemd in Apr2003, heeft een ambtstermijn van 21.58 jaar. De totale jaarlijkse vergoeding van { bedraagt CHF 2.65M, bestaande uit 21.8% salaris en 78.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.45% van de aandelen van het bedrijf, ter waarde € 7.86M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 6.6 jaar.

Belangrijke informatie

Andrea Pfeifer

Algemeen directeur

CHF 2.7m

Totale compensatie

Percentage CEO-salaris	21.8%
Dienstverband CEO	21.6yrs
Eigendom CEO	2.4%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	6.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Andrea Pfeifer's beloning veranderd ten opzichte van AC Immune's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CHF 40m
Jun 30 2024	n/a	n/a	-CHF 61m
Mar 31 2024	n/a	n/a	-CHF 55m
Dec 31 2023	CHF 3m	CHF 578k	-CHF 54m
Sep 30 2023	n/a	n/a	-CHF 68m
Jun 30 2023	n/a	n/a	-CHF 67m
Mar 31 2023	n/a	n/a	-CHF 69m
Dec 31 2022	CHF 2m	CHF 558k	-CHF 71m
Sep 30 2022	n/a	n/a	-CHF 73m
Jun 30 2022	n/a	n/a	-CHF 76m
Mar 31 2022	n/a	n/a	-CHF 75m
Dec 31 2021	CHF 2m	CHF 530k	-CHF 73m
Sep 30 2021	n/a	n/a	-CHF 71m
Jun 30 2021	n/a	n/a	-CHF 74m
Mar 31 2021	n/a	n/a	-CHF 71m
Dec 31 2020	CHF 2m	CHF 520k	-CHF 62m
Sep 30 2020	n/a	n/a	-CHF 62m
Jun 30 2020	n/a	n/a	-CHF 25m
Mar 31 2020	n/a	n/a	-CHF 26m
Dec 31 2019	CHF 2m	CHF 510k	CHF 45m
Sep 30 2019	n/a	n/a	CHF 50m
Jun 30 2019	n/a	n/a	CHF 18m
Mar 31 2019	n/a	n/a	CHF 24m
Dec 31 2018	CHF 2m	CHF 455k	-CHF 51m
Sep 30 2018	n/a	n/a	-CHF 32m
Jun 30 2018	n/a	n/a	-CHF 27m
Mar 31 2018	n/a	n/a	-CHF 29m
Dec 31 2017	CHF 2m	CHF 404k	-CHF 26m

Compensatie versus markt: De totale vergoeding ($USD 2.96M ) Andrea } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.03M ).

Compensatie versus inkomsten: De vergoeding van Andrea is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andrea Pfeifer (67 yo)

21.6yrs

Tenure

CHF 2,650,000

Compensatie

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrea Pfeifer	Co-Founder	21.6yrs	CHF 2.65m	2.45% € 7.9m
Christopher Roberts	CFO & VP of Finance	2.6yrs	geen gegevens	0.013% € 40.9k
Piergiorgio Donati	Chief Technical Operations Officer	5.8yrs	geen gegevens	0.025% € 79.6k
Jean-Fabien Monin	Chief Administrative Officer	9.3yrs	geen gegevens	0.32% € 1.0m
Howard Donovan	Chief HR Officer	2.6yrs	geen gegevens	0.020% € 65.4k
Madiha Derouazi	Chief Scientific Officer	less than a year	geen gegevens	0.0032% € 10.3k
Gary Waanders	Senior VP of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Alexandre Caratsch	General Counsel	no data	geen gegevens	geen gegevens
Julian Snow	VP of U.S. Finance & Corporate Development	2.6yrs	geen gegevens	geen gegevens
David Hickman	Head of AD - SME	14.8yrs	geen gegevens	geen gegevens
Joseph Wettstein	Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer	8.8yrs	geen gegevens	geen gegevens
Oliver Sol	VP & Head of Clinical Development	no data	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IMR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrea Pfeifer	Co-Founder	8.5yrs	CHF 2.65m	2.45% € 7.9m
Jean-Marie Lehn	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Claude Nicolau	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Douglas Williams	Independent Non-Executive Chairman	6.6yrs	CHF 179.00k	0.039% € 126.4k
Alf E. Lindberg	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Detlev Riesner	Member of Scientific Advisory Board	no data	CHF 5.00k	geen gegevens
Fred Van Leuven	Member of Scientific Advisory Board	no data	CHF 105.00k	geen gegevens
I. Rosenberg	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
M. Monsigny	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
E. Lestringant	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Monika Butler	Independent Vice Chair	3.1yrs	CHF 163.00k	0.0092% € 29.7k
Andreas Monsch	Head of Clinical Advisory Board	no data	geen gegevens	geen gegevens

6.6yrs

Gemiddelde duur

74.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMR wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.6 jaar).

AC Immune Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

AC Immune SA, Annual General Meeting, Jun 20, 2024

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

AC Immune SA Announces Executive Changes

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

New major risk - Revenue and earnings growth

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

New major risk - Revenue and earnings growth

AC Immune SA Announces Executive Changes

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

New 90-day high: €5.57

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: €5.17

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

AC Immune Sa Appoints Carl H. June as Board of Directors

AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer

Revenue beats expectations

Third quarter 2020 earnings released: CHF0.26 loss per share

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

New 90-day low: €3.83

AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

New 90-day low: €4.25

First half earnings released

New 90-day high - €7.95

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd